Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515
View directory record Official record
Conditions
Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions
AZ-3102, Placebo
Drug
Lead sponsor
Azafaros B.V.
Industry
Eligibility
4 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

NCT03220854
View directory record Official record
Conditions
Solid Tumor
Interventions
Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 25, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About Sickle Cell Disease In Adult Patients

NCT05407805
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Electronic Diary
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Terminated Not applicable Interventional

Surgical vs. Lifestyle in Obese Older Adults

NCT03137329
View directory record Official record
Conditions
Obesity
Interventions
Exercise program, Nutrition, WLS
Behavioral · Dietary Supplement · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
55 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Thriving in the Midst of Moral Pain: The Acceptability and Feasibility of Acceptance and Commitment Therapy for Moral Injury (ACT-MI) Among Warzone Veterans

NCT03760731
View directory record Official record
Conditions
Moral Injury
Interventions
Acceptance and Commitment Therapy for Moral Injury (ACT-MI), Present Centered Therapy for Moral Injury (PCT-MI)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

NCT01606761
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Sirukumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
81
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 25, 2026, 5:59 AM EDT
Withdrawn Phase 3 Interventional

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160
View directory record Official record
Conditions
Thoracic, Pulmonary Disease
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845
View directory record Official record
Conditions
Healthy
Interventions
rLP2086, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 25 Years
Enrollment
3,301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Remote Ischemic Conditioning in HSCT

NCT04808167
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantations
Interventions
autoRIC®
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Orca-T, Standard-of-Care
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

NCT02453256
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Placebo, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
El Cajon, California • Fullerton, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection

NCT04817865
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
Diagnostic Test
Lead sponsor
Pathnostics
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Barrington, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional

Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors

NCT02786797
View directory record Official record
Conditions
Breast Cancer
Interventions
MBSR(BC) 6 Week Program, BCES 6 Week Program
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Sarasota, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

NCT01018069
View directory record Official record
Conditions
Leukemia
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

NCT03020160
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Sacramento, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Not applicable Interventional

The Effect of Self-Forgiveness on Self-Stigma in Addiction.

NCT03971097
View directory record Official record
Conditions
Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions
Six Step Model of Self-Forgiveness, Treatment as Usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
McKeesport, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 25, 2026, 5:59 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Traveler's Diarrhea (TD) Automated Process

NCT00751777
View directory record Official record
Conditions
Prevention of Travelers' Diarrhea
Interventions
heat-labile enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Vallejo, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 25, 2026, 5:59 AM EDT
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 5:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Caring for Caregivers With Mind-body Exercise

NCT04019301
View directory record Official record
Conditions
Caregiver Distress, Physical Function, Quality of Life
Interventions
Baduanjin Qigong, Community-based, Baduanjin Qigong, Internet-based
Other
Lead sponsor
University of Houston
Other
Eligibility
35 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 25, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

NCT02160145
View directory record Official record
Conditions
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan (OPC-41061), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 25, 2026, 5:59 AM EDT